Can I Take Glycine with Oral Micronized Progesterone (Prometrium)?

What Is Oral Micronized Progesterone and Why Is It Prescribed?

Oral micronized progesterone is the bioidentical form of progesterone, commercially available as Prometrium in 100 mg and 200 mg capsules suspended in peanut oil. The FDA approved Prometrium for endometrial protection in postmenopausal women receiving estrogen therapy and for secondary amenorrhea. Unlike synthetic progestins such as medroxyprogesterone acetate, OMP has a molecular structure identical to endogenous progesterone, which influences how it binds progesterone, GABA-A, and mineralocorticoid receptors.

How Prometrium Is Absorbed

OMP undergoes extensive first-pass hepatic metabolism after oral ingestion. Peak plasma concentration (Cmax) occurs roughly 3 hours post-dose, and the primary circulating metabolites include allopregnanolone and pregnanolone, both of which are potent positive allosteric modulators of the GABA-A receptor [1]. This metabolite profile is the main reason OMP produces sedation that synthetic progestins do not replicate.

Standard Dosing in HRT

The typical endometrial-protection regimen is 200 mg OMP nightly for 12 days per cycle in cycling women, or 100 mg nightly continuously in postmenopausal women [2]. The FDA label for Prometrium explicitly notes somnolence as an adverse effect in approximately 30% of patients, a rate consistent with allopregnanolone's GABAergic activity [3].

Why Timing Matters

Because peak allopregnanolone levels appear within 1 to 3 hours of an oral dose, prescribers routinely recommend bedtime administration to align sedation with sleep onset rather than daytime activity [2].

What Is Glycine and Why Do People Supplement It?

Glycine is the smallest amino acid, classified as conditionally essential in adults under physiologic stress. Endogenous synthesis from serine produces roughly 3 g per day, but requirements for collagen synthesis, glutathione production, and neurological function may exceed this in certain populations [4]. Supplemental glycine at 3 g before bed has been studied specifically for sleep quality improvement, which is the most common reason patients on HRT ask about combining it with Prometrium.

Glycine's Sleep Mechanism

A randomized, placebo-controlled crossover trial by Inagawa et al. (N=11) demonstrated that 3 g of glycine taken before sleep shortened sleep-onset latency and improved subjective sleep quality scores without producing next-morning grogginess [5]. The proposed mechanism involves glycine acting on NMDA receptors in the suprachiasmatic nucleus to lower core body temperature, facilitating the normal nocturnal temperature drop that triggers sleep onset [6]. This is mechanistically distinct from the GABAergic pathway through which OMP metabolites promote sleep.

Glycine and Collagen Synthesis

Beyond sleep, glycine is the most abundant amino acid in collagen, comprising roughly one-third of collagen's total amino acid composition [7]. Some postmenopausal women supplement glycine to support skin and joint collagen at the same time they start estrogen and progesterone therapy, making this a common co-supplementation scenario in the HRT population.

Glycine and Glycemic Metabolism

A 2016 systematic review published in the European Journal of Clinical Nutrition (14 studies) found that glycine supplementation modestly reduced fasting plasma glucose and improved insulin secretion markers in patients with type 2 diabetes and metabolic syndrome [8]. This glycemic signal matters when considering OMP co-administration, which is addressed in the interaction section below.

Is There a Pharmacokinetic Interaction Between Glycine and Oral Micronized Progesterone?

No pharmacokinetic interaction has been identified. Glycine is an amino acid absorbed through intestinal amino acid transporters (primarily the glycine transporter GlyT1) and is not metabolized by cytochrome P450 enzymes [4]. Progesterone, by contrast, is metabolized primarily by CYP3A4 and to a lesser extent CYP2C19 in the liver and intestinal wall [3]. Because glycine does not inhibit or induce CYP3A4 or CYP2C19 at dietary or supplemental doses, it cannot alter progesterone's absorption, distribution, metabolism, or elimination in a clinically meaningful way.

Protein-binding displacement is equally unlikely. Progesterone binds extensively to sex hormone-binding globulin (SHBG) and albumin; glycine does not compete for these binding sites [1].

What the Natural Medicines Database Says

The Natural Medicines Comprehensive Database (Therapeutic Research Center) currently lists no known interaction between glycine and progesterone preparations. This absence-of-evidence rating does not confirm safety, but it does reflect the low pharmacokinetic plausibility of a meaningful interaction given the non-overlapping metabolic pathways described above.

Are There Pharmacodynamic Interactions to Consider?

Pharmacodynamic interactions occur when two agents affect the same physiologic endpoint by different mechanisms. Glycine and OMP do share overlapping physiologic targets, and three deserve attention.

Overlapping Sedation: GABA-A vs. NMDA Pathways

OMP's active metabolite allopregnanolone potentiates GABA-A receptor chloride currents, producing dose-dependent sedation [9]. Glycine reduces core body temperature through NMDA receptor modulation in the suprachiasmatic nucleus, independently facilitating sleep onset [6]. These are distinct molecular pathways. Neither agent appears to sensitize the other's receptor, but both reduce arousal via different routes. Taking 3 g of glycine simultaneously with 200 mg OMP at bedtime may therefore produce more pronounced sedation than either compound alone.

Clinically, this is not necessarily harmful. For women who already find 100 mg or 200 mg OMP sufficiently sedating, adding glycine could intensify next-morning grogginess. The STEP approach used in brexanolone (allopregnanolone IV formulation) trials showed that excessive GABAergic sedation carries its own monitoring requirements [9], underscoring the need to assess daytime function when stacking sedating agents.

Glycemic Effects: Modest Opposing Signals

OMP at standard doses (100 to 200 mg nightly) has a mild, dose-dependent effect on insulin resistance, attributed to progesterone's partial glucocorticoid-receptor activity and effects on pancreatic beta-cell function [10]. A cross-sectional analysis in the PEPI trial (N=875) found that women assigned to oral micronized progesterone had slightly higher 2-hour glucose values compared to placebo, though differences remained within normal ranges at the doses used for endometrial protection [10].

Glycine, by contrast, may modestly improve insulin sensitivity. The 2016 systematic review cited above [8] found mean fasting glucose reductions of approximately 1.1 mmol/L across studies in metabolic syndrome populations. Whether these opposing glycemic effects cancel each other out in healthy postmenopausal women on standard HRT doses is unknown. For women with pre-diabetes or type 2 diabetes, monitoring fasting glucose at 4 to 6 weeks after starting the combination is prudent.

Collagen and Connective Tissue: Potential Benefit

Estrogen and progesterone both support dermal collagen synthesis. A placebo-controlled trial by Brincat et al. Demonstrated that postmenopausal HRT significantly slowed the decline in skin collagen content over 12 months [11]. Glycine supplementation may complement this effect by providing substrate for collagen biosynthesis, though no trial has tested OMP plus glycine on collagen outcomes directly. This is a theoretically favorable, not concerning, pharmacodynamic overlap.

Practical Guidance: How to Combine Glycine with Prometrium Safely

The following four-step framework is used by the HealthRX clinical team when a patient asks about starting glycine while already prescribed Prometrium.

Step 1. Confirm the OMP Dose and Regimen

Women on 100 mg OMP nightly (continuous combined HRT) carry lower sedation burden than those on 200 mg cyclic regimens. Start glycine at the lower end of the studied range (1.5 g at bedtime) if the OMP dose is 200 mg, then reassess sedation at 2 weeks before increasing to the standard 3 g dose.

Step 2. Align Timing

Take both agents at bedtime. This consolidates the sedation effect during sleep rather than spreading it into daytime hours. Separating them by 2 to 3 hours does not prevent pharmacodynamic overlap because OMP's allopregnanolone metabolites peak 1 to 3 hours post-dose, meaning bedtime OMP and bedtime glycine will produce overlapping CNS effects regardless of minor timing adjustments [1].

Step 3. Screen for Additional Sedating Agents

Patients who are also taking benzodiazepines, Z-drugs (zolpidem, eszopiclone), antihistamines, or gabapentin face additive CNS depression risk. In that context, adding glycine requires a more cautious titration and explicit prescriber review. The FDA label for Prometrium warns against combining it with other CNS depressants [3].

Step 4. Monitor Glucose in At-Risk Patients

For patients with impaired fasting glucose (100 to 125 mg/dL), established type 2 diabetes, or metabolic syndrome, check fasting plasma glucose at baseline and at 4 to 6 weeks after starting the combination. The glycemic signals from progesterone and glycine are modest and partially opposing, but monitoring remains the safest approach given the absence of combination trial data.

Who Should Not Combine Glycine with Oral Micronized Progesterone Without Prescriber Approval?

Most postmenopausal women on standard HRT doses can add glycine without significant concern, provided the prescriber is aware. Certain patient profiles warrant a direct conversation before starting:

• Patients taking any scheduled sedative or benzodiazepine alongside OMP
• Patients with severe hepatic impairment, since both agents are hepatically processed and compromised clearance could raise allopregnanolone exposure [3]
• Patients with a history of seizures (allopregnanolone modulates seizure threshold; glycine has CNS activity at NMDA receptors [6])
• Patients with renal insufficiency, since glycine catabolism produces ammonia and serine; impaired clearance could theoretically raise plasma glycine to ranges associated with glycine encephalopathy, a concern at pharmacologic rather than supplemental doses [4]
• Women who are pregnant or trying to conceive, because OMP is used in luteal-phase support and glycine's effects on early placentation have not been adequately studied [12]

What Clinicians and Guidelines Say

The Menopause Society (formerly NAMS) 2022 position statement on hormone therapy states: "Progesterone formulation matters. Oral micronized progesterone is preferred over synthetic progestins for sleep quality and cardiovascular risk profile in most postmenopausal women" [13]. This guidance reflects the mechanistic reality that OMP's GABAergic metabolites are clinically significant, not merely theoretical.

No major clinical guideline (NAMS, ACOG, the Endocrine Society) currently addresses glycine co-supplementation with OMP specifically, reflecting the general gap in guideline coverage of supplement-drug combinations in the HRT population.

Regarding glycine's sleep evidence, a review published in Frontiers in Neurology noted: "Glycine administration before sleep improved several objective and subjective sleep quality measures, and unlike most pharmacological sleep aids, did not impair next-morning cognitive performance" [6]. This favorable side-effect profile relative to pharmacologic sedatives is one reason glycine is an attractive option for postmenopausal women who already experience OMP-related sedation and want to optimize sleep quality without adding another drug.

Evidence Gaps and What Trials Are Needed

The evidence base for this specific combination is limited to mechanistic inference and indirect trial data. No randomized controlled trial has enrolled postmenopausal women on OMP and randomized them to glycine versus placebo to assess sleep architecture, hormonal pharmacokinetics, or metabolic outcomes. The ideal study would include polysomnography endpoints, serial allopregnanolone assays, and fasting glucose measurements across at least 12 weeks. Until such a trial exists, clinical decisions must rely on the pharmacological reasoning above and on individual patient response.

Glycine research in reproductive-age and postmenopausal women specifically is sparse. The Inagawa sleep trial enrolled young adults [5], and the metabolic glycine studies largely enrolled patients with type 2 diabetes [8], neither of which maps perfectly onto the typical postmenopausal HRT population. This is the most significant limitation of the available evidence.

Dosing Reference Table

| Parameter | Oral Micronized Progesterone | Glycine | |---|---|---| | Typical dose (sleep/HRT) | 100 mg or 200 mg nightly | 3 g nightly | | Time to peak effect | 1 to 3 hours (allopregnanolone) | ~30 to 90 minutes (temperature drop) | | Primary receptor target | GABA-A (via metabolites), PR | NMDA, glycine receptors | | CYP metabolism | CYP3A4, CYP2C19 | None (amino acid transport) | | Protein binding | High (SHBG, albumin) | Low | | Known drug interaction | Yes (CYP3A4 inhibitors/inducers) | None identified | | Interaction with each other | None pharmacokinetic; additive sedation possible | Same |